Carcinogenesis, Vol. 20, No. 7, 1153-1160,
July 1999
© 1999 Oxford University Press
Commentary |
The tamoxifen dilemma
MRC Toxicology Unit, Hodgkin Building, Lancaster Road, Leicester LE1 9HN, UK
The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. It could also play a role as a breast cancer chemopreventive agent. However, epidemiological studies in both tamoxifen-treated breast cancer patients and in healthy women have shown that treatment results in a small increase in the incidence of endometrial cancers. While the use of tamoxifen in breast cancer patients is clearly justified, the situation for its use as a chemopreventive agent in healthy women is not so clear cut. Reasons for caution come from studies in rats that show that tamoxifen is a genotoxic mutagenic liver carcinogen. Initiation of tumours in the rat is the result of metabolic activation of tamoxifen by CYP enzymes to an electrophile(s) that binds irreversibly to DNA. This is not related to the oestrogen receptor status of the tissue. The extent of DNA damage, detected by 32P-post-labelling or accelerator mass spectrometry, is dependent both on the dose and the length of exposure. Studies have been carried out to see if such binding occurs in the uterine endometrium from tamoxifen-treated women. Results are presently inconclusive, but if such irreversible DNA binding occurs, it is at very low levels. Based on a mechanistic understanding of tamoxifen-induced liver carcinogenesis in the rat, it seems that in humans hepatic DNA damage will be close to the limit of detection by 32P-post-labelling and liver cancer will not be a significant carcinogenic risk. We cannot be certain of the mode of action of tamoxifen that results in the increase in endometrial cancers in treated women but it seems unlikely that this will be associated with a classical genotoxic mechanism.
Abbreviations: ER, oestrogen receptor; ICI 182 780, 7
-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]estra-1,3,5(10)-triene-3,17ß-diol; raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone; SERMS, selective oestrogen receptor modulators; tamoxifen, (Z)-1-[4-[(dimethylamino)ethoxy]phenyl]-1,1-diphenyl-1-butene; toremifene, (Z)-4-chloro-1-[4-[2(N,N-dimethylamino)ethoxy]phenyl]-1-butene.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. P. Tryndyak, L. Muskhelishvili, O. Kovalchuk, R. Rodriguez-Juarez, B. Montgomery, M. I. Churchwell, S. A. Ross, F. A. Beland, and I. P. Pogribny Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis Carcinogenesis, August 1, 2006; 27(8): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Apak and M. W. Duffel INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.E. Heres-Pulido, I. Duenas-Garcia, L. Castaneda-Partida, A. Sanchez-Garcia, M. Contreras-Sousa, A. Duran-Diaz, and U. Graf Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster Mutagenesis, May 1, 2004; 19(3): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mizutani, T. Okada, S. Shibutani, E. Sonoda, H. Hochegger, C. Nishigori, Y. Miyachi, S. Takeda, and M. Yamazoe Extensive Chromosomal Breaks Are Induced by Tamoxifen and Estrogen in DNA Repair-Deficient Cells Cancer Res., May 1, 2004; 64(9): 3144 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats Carcinogenesis, April 1, 2001; 22(4): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, J. T. Reardon, N. Suzuki, and A. Sancar Excision of Tamoxifen-DNA Adducts by the Human Nucleotide Excision Repair System Cancer Res., May 1, 2000; 60(10): 2607 - 2610. [Abstract] [Full Text]
|
|
|
|
|
|
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients Carcinogenesis, April 1, 2000; 21(4): 845 - 847. [Abstract] [Full Text] [PDF]
|
|